- DokumentFormal Meetings Between the FDA and Biosimilar Biological Product Sponsors or Applicants November 2015 Procedural 15085fnlhochgeladen vonMarkbot1999
- DokumentBioeqivalence Recommendations for Specific Products 8857fnl.pdfhochgeladen vonMarkbot1999
- DokumentWaiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System DRAFT May 2015 Rev 1 ucm070246.pdfhochgeladen vonMarkbot1999
- DokumentBioeqivalence Recommendations for Specific Products 8857fnlhochgeladen vonMarkbot1999
- DokumentWaiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System DRAFT May 2015 Rev 1 ucm070246.pdfhochgeladen vonMarkbot1999
- DokumentDesignation of Official Names and Proper Names for Certain Biological Products Propose Rule 2015-21382hochgeladen vonMarkbot1999
- DokumentStability Guidance & Draft Q&A Guidance considerations FDA Small Business WEBINAR 2013-11-04 UCM373234.pdfhochgeladen vonMarkbot1999
- DokumentReferencing Approved Drug Products in ANDA Submissions DRAFT 01-2017 Generics.pdfhochgeladen vonMarkbot1999
- DokumentUpdating ANDA Labeling After the Marketing Application for the Reference Listed Drug Has Been Withdrawn July 2016 Generics 3048879dft.pdfhochgeladen vonMarkbot1999
- DokumentInspections and ANDA Review CDER OC OMQ’s Role Francis Godwin OMQ CDER GPhA Fall 2016hochgeladen vonMarkbot1999
- DokumentGood ANDA Submission Practices DRAFT January 2018 Generics.pdfhochgeladen vonMarkbot1999
- DokumentRLD - reference standard - BOS draft guidance webinar 1-18-17.pdfhochgeladen vonMarkbot1999
- DokumentMAPP 5240.3 Rev.2 Prioritization of the Review of Original ANDAs, Amendments, and Supplements.pdfhochgeladen vonMarkbot1999
- DokumentOff-Patent Off-Exclusivity Drug List with no Generic 2017-10-30.pdfhochgeladen vonMarkbot1999
- DokumentAssessing Adhesion with Transdermal Delivery Systems and Topical Patches for ANDAs Draft June 2016 Generic Drugs.pdfhochgeladen vonMarkbot1999
- DokumentGood ANDA Submission Practices DRAFT January 2018 Generics.pdfhochgeladen vonMarkbot1999
- DokumentControlled Correspondence Related to Generic Drug Development September 2015 Generics.pdfhochgeladen vonMarkbot1999
- DokumentGood Abbreviated New Drug Application Assessment Practices MAPP 5241.3 2018-01-03hochgeladen vonMarkbot1999
- DokumentANDA Submissions Refuse to Receive for Lack of Justification of Impurity Limits 20160810.pdfhochgeladen vonMarkbot1999
- DokumentANDA Submissions Amendments and Easily Correctable Deficiencies Under GDUFA July 2014 Generic Drugs DRAFT.pdfhochgeladen vonMarkbot1999
- DokumentANDA Submissions Refuse-to-Receive Standards Guidance for Industry May 2015 Generic Drugs Revision 1.pdfhochgeladen vonMarkbot1999
- DokumentANDA Submissions Refuse-to-Receive Standards December 2016 Generics Revision 2.pdfhochgeladen vonMarkbot1999
- DokumentANDAs Stability Testing of Drug Substances and Products June 2013 Generics 10956fnl ANDAs_ 5-6-2013 CLEAN.pdfhochgeladen vonMarkbot1999
- DokumentANDAs Stability Testing of Drug Substances and Products Questions and Answers May 2014 Generics CDER2013213 guidance May2.pdfhochgeladen vonMarkbot1999
- DokumentANDA Submissions Prior Approval Supplements Under GDUFA October 2016 Genericshochgeladen vonMarkbot1999
- DokumentProviding Regulatory Submissions in Electronic and Non-Electronic Format—Promotional Labeling and Advertising Materials for Human Prescription Drugs DRAFT April 2015hochgeladen vonMarkbot1999
- DokumentANDA Submissions Amendments and Easily Correctable Deficiencies Under GDUFA July 2014 16478dft_07-09-14.pdfhochgeladen vonMarkbot1999
- DokumentANDA Submissions Prior Approval Supplements Under GDUFA DRAFT July 2014 16479dft_07-09-14.pdfhochgeladen vonMarkbot1999
- DokumentSelf-Identification of Generic Drug Facilities Sites and Organizations September 2016 Generics GDUFA Self ID Final Guidance2hochgeladen vonMarkbot1999
- DokumentCommunications With Industry With Respect to Pre-GDUFA Year Three ANDAs MAPP 5200.3 Rev. 1hochgeladen vonMarkbot1999
- DokumentWebinar - Amendments and Easily Correctable Deficiencies Under GDUFA 063014hochgeladen vonMarkbot1999
- DokumentDay2.4 - Mozzachio - Post-Approval and Surveillance Inspectionhochgeladen vonMarkbot1999
- DokumentDay2.2 - Lionberger - GDUFA Regulatory Sciencehochgeladen vonMarkbot1999
- DokumentDay1.7 - Song - Completeness Assessment for TYpe II API DMF Under GDUFAhochgeladen vonMarkbot1999
- DokumentDay1.6 - Zhang - DMFs With a GDUFA Perspectivehochgeladen vonMarkbot1999
- DokumentDay1.5 - Shaw - Drug Master File (DMF) Basicshochgeladen vonMarkbot1999
- DokumentDay1.4 - Lantzy - Optimizing Your eCTD ANDAhochgeladen vonMarkbot1999
- DokumentDay1.3 - Lee - A Filing Reviewer's Perspectivehochgeladen vonMarkbot1999
- DokumentDay2.6 - Park - GDUFA Review Efficiency Enhancementshochgeladen vonMarkbot1999
- DokumentDay1.2 - Young - An Overview of the Draft Guidance for Industry - ANDA Submissions RTRhochgeladen vonMarkbot1999
- DokumentFDA Perspectives - Scientific Considerations of Forced Degradation Studies in ANDA Submissions Ragine Maheswaran MAY 2012hochgeladen vonMarkbot1999
- DokumentProcess Validation General Principles and Practices January 2011 Revision 1 9365fnlhochgeladen vonMarkbot1999
- Dokument- 879 CHAPTER 64E-16 BIOMEDICAL WASTEhochgeladen vonMarkbot1999
- DokumentVitamin B New Researchhochgeladen vonMarkbot1999